Fintel reports that on January 8, 2025, Leerink Partners downgraded their outlook for Accolade (NasdaqGS:ACCD) from ...

Stock analysts at Leerink Partnrs issued their FY2029 EPS estimates for AbbVie in a research report issued on Monday, January ...

Research analysts at Leerink Partnrs lowered their Q4 2024 earnings per share estimates for Laboratory Co. of Amer ...

Leerink downgraded Accolade (ACCD) to Market Perform from Outperform with a price target of $7.03, down from $9.50, after the company agreed to ...

Leerink Partners analyst Thomas Smith has reiterated their bullish stance on VRDN stock, giving a Buy rating yesterday.Stay Ahead of the ...

Alongside plans to spin out a new company, the Belgian drugmaker said it will cut some 300 positions, or about 40% of its ...

In a rare move, the FDA recommended a minimum of 5% weight-loss for drug developers seeking to establish the efficacy of ...

Look for renewed investment driven by lower interest rates in the new year, and a continued focus on late-stage assets, ...

Cantor Fitzgerald has recently initiated Aquestive Therapeutics Inc (AQST) stock to Overweight rating, as announced on December 17, 2024, according to Finviz. Earlier, on May 10, 2024, Leerink ...

On Tuesday, Vincerx Pharma Inc (VINC) stock saw a modest uptick, ending the day at $0.21 which represents no change from the prior close of of $0.21. The stock opened at $0.21 and touched a low of ...

Biotech M&A is heating up, and Mirum Pharmaceuticals stands out. Discover why analysts predict a 50% upside and long-term ...

Qure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the pricing of its underwritten public offering of 4 ...